Peptide News Digest

Australia Approves the Wegovy Pill, Bariatric Surgery After GLP-1 Drugs Fail, Food Noise in Nearly 1 in 5 Adults

Australia's TGA clears the Wegovy pill, surgery helps after GLP-1 drugs fail, and a survey finds 18% of U.S. adults report frequent food noise.

11 stories · Covering regulatory, research, industry

Editor's Note

Australia's drug regulator approved the Wegovy pill on Tuesday, but the TGA still has to check packaging and production, there is no price, and the government drug subsidy scheme pays for these drugs only in type 2 diabetes. The same week, an independent MP used the Richard Norton coronial finding to press for a parliamentary inquiry into telehealth businesses that prescribe unapproved peptides. Coverage remains the sticking point in the U.S. too: a state rule bars Ohio Medicaid from paying for GLP-1 drugs for adult obesity, and nursing homes pay out of pocket for residents in a Part A stay. Cleveland Clinic data offer some reassurance for people the drugs did not help, with gastric bypass producing two-year weight loss similar to that of patients who never took them. Beyond GLP-1 drugs, Eli Lilly scientists built a model that predicts how fast an injected peptide is absorbed from its sequence alone, and three lab studies used peptides to stiffen cancer cells, protect mouse skin from UVB, and steer mRNA particles to the spleen.

Correction (November 3, 2026): An earlier version of the first item's headline called the Wegovy pill Australia's first oral GLP-1. Rybelsus, a lower-dose oral semaglutide tablet for type 2 diabetes, was already available in Australia; the Wegovy pill is the first GLP-1 tablet approved there for weight management.

Regulatory

Australia's TGA Approves Novo Nordisk's Wegovy Pill, Its First GLP-1 Tablet for Weight Loss, With No Launch Date or Price Yet

The Therapeutic Goods Administration approved Novo Nordisk's oral semaglutide tablet on Tuesday, November 3, in 1.5, 4, 9, and 25 mg strengths for adults with obesity and for lowering cardiovascular risk, ABC News reported. The TGA still has to review packaging and production before the pill can be released, no price has been set, and under current rules the Pharmaceutical Benefits Scheme subsidizes these drugs only for type 2 diabetes. Eli Lilly's orforglipron is still awaiting a TGA decision.

#oral-semaglutide #wegovy #tga #australia #novo-nordisk
Regulatory

Independent MP Monique Ryan Presses Australia's Health Minister for a Telehealth Inquiry After the Richard Norton Peptide Finding

After a Victorian coroner linked actor Richard Norton's death to injected CJC-1295 and ipamorelin, independent MP Dr Monique Ryan renewed her call for the Health Minister to refer telehealth and online prescribing to the House Health Committee, Retail Pharmacy reported. She first wrote to the minister in August; the inquiry she wants would examine companies that combine telehealth, pharmacy, and retail, the routes that let unapproved peptides be prescribed and compounded, and gaps between the TGA, AHPRA, and the states. "This inquiry is about protecting good telehealth from profit-driven prescribing, not winding it back," she said.

#telehealth #australia #cjc-1295 #ipamorelin #compounding
Regulatory

Obesity Action Coalition Pushes Ohio to Lift the Rule That Bars Medicaid Coverage of GLP-1 Drugs for Adult Obesity

Ohio Medicaid covers GLP-1 drugs for type 2 diabetes, heart risk reduction, sleep apnea, MASH, and obesity in patients under 18, but an exclusion in the state's administrative code blocks coverage for adult obesity, and the agency said it "cannot simply start covering these drugs under current policy," the Journal-News reported. Sarah Bramblette of the Obesity Action Coalition is pushing for a change, which would require formal rulemaking reviewed by the Joint Committee on Agency Rule Review or new legislation. KFF counts 13 state Medicaid programs that covered the drugs for weight management as of early 2026.

#medicaid #ohio #glp-1 #obesity-action-coalition
Research

Cleveland Clinic: Gastric Bypass Still Produced Large Two-Year Weight Loss in Patients Who Quit or Barely Responded to Semaglutide or Tirzepatide

In a retrospective study of 4,929 adults with a BMI of 35 or more who had bariatric surgery from 2018 to 2024, 61 had stopped semaglutide or tirzepatide because of side effects and 207 had lost little weight on them (an estimated 1.5% over two years), Ali Aminian and colleagues reported in Annals of Surgery. Two years after gastric bypass, poor responders without diabetes lost an estimated 35.8% of body weight, compared with 33.3% for patients who never took the drugs; after sleeve gastrectomy the figures were 14.3% and 23.6%. Among poor responders, bypass was linked to 14.9 percentage points more weight loss than sleeve, though the drug groups were small.

#bariatric-surgery #semaglutide #tirzepatide
Research

Penn State Survey: 18% of U.S. Adults Report Frequent 'Food Noise,' and Current GLP-1 Users Were More Likely to Say So

In a nationally representative online survey of 1,000 U.S. adults in May 2026, 17.98% said they often or always experience food noise, meaning intrusive thoughts about food, Penn State nutrition researchers Daisuke Hayashi and Travis Masterson reported in Obesity Science and Practice. Frequent food noise was reported by 25.76% of current and 26.78% of former GLP-1 users, compared with 16.30% of non-users; in adjusted analyses, loss of control over eating (odds ratio 5.95) was the strongest predictor, followed by current GLP-1 use (1.60) and female sex (1.47). The study used a single question, and Masterson said the GLP-1 finding "could arise from an awareness issue."

#food-noise #glp-1 #survey #appetite
Industry

Numerator: Households That Stopped GLP-1 Drugs Still Spent Less at Subway, Arby's, and McDonald's but More at Costco

Consumer data firm Numerator estimates that 12.3 million U.S. households include someone who has stopped a GLP-1 weight-loss drug, Food Business News reported. In the 12 months ended September 30, spending per household by these lapsed users fell 15% at Subway, 6.8% at Arby's, 4.5% at Domino's, and 1.8% at McDonald's, while it rose 3.2% at Costco and 1.3% at Walmart; their overall grocery spending fell 1.8%, compared with 2.6% for households still on the drugs. Numerator's quarterly tracker drew more than 95,000 survey responses linked to purchase data.

#food-industry #consumer-spending #glp-1 #numerator
Industry

Nursing Homes Absorb GLP-1 Costs as 30% to 40% of New Admissions at One New Jersey Operator Arrive on the Drugs

Lisa Chubb, chief nursing officer of New Jersey-based Venza Care, told Skilled Nursing News that about 30% to 40% of newly admitted residents are on GLP-1 drugs. For residents in a Medicare Part A stay the nursing home pays for the medication, and residents covered for weight loss through the Medicare GLP-1 Bridge pay a $50 monthly fee; Jessie McGill of the American Association for Post-Acute Care Nursing said a lasting fix would need Congress to exclude high-cost drugs like GLP-1s from consolidated billing, as it does for chemotherapy and dialysis drugs. Nurses also need to watch older residents for muscle loss, weakness, and poor food intake.

#nursing-homes #medicare #medicare-glp-1-bridge #long-term-care
Research

Eli Lilly Scientists Build a Machine-Learning Model That Predicts How Fast Injected Peptides Are Absorbed From Their Sequence

Lilly researchers compiled 41 subcutaneous absorption rate constants measured in human clinical studies of unmodified, fatty-acid-acylated, and protein-conjugated peptides, then trained models on sequence embeddings and 30 physics-based molecular descriptors, they reported in Molecular Pharmaceutics. The best model (NGBoost) reached R² = 0.850 in leave-one-out cross-validation, with molecular weight, net charge, hydrophobicity, and acyl chain features driving its predictions. The authors say it could help rank drug candidates before animal or human data exist; the training set is small.

#machine-learning #drug-delivery #eli-lilly
Research

Tongji University Team Forms Stiff Peptide Nanosheets Inside Inflammatory Breast Cancer Cells With UV Light, Slowing Tumors 72% in Mice

Tongji University researchers used 365 nm UV light and a photoinitiator to polymerize a histidine-based monomer inside inflammatory breast cancer cells, forming peptide nanosheets about 30 nm thick that stiffened the cells, reduced their migration and invasion, and triggered a paraptosis-like cell death, they reported in ACS Nano. In mice with implanted tumors, light delivered through an optical fiber inhibited tumor growth by 72.2% without overt systemic toxicity; there is no human data.

#breast-cancer #cancer #nanomedicine
Research

Ocean University of China's Donkey-Hide Collagen Peptide Fraction CCAP1 Eased UVB Skin Damage in Mice When Taken by Mouth

Researchers at Ocean University of China's Marine Biomedical Research Institute of Qingdao made CCAP1, a type I collagen oligopeptide fraction of about 1.7 kDa from Colla Corii Asini (donkey-hide gelatin), and gave it orally at 100 or 200 mg/kg a day for 28 days to UVB-irradiated mice, reporting in Molecules. It reduced epidermal thickening, restored skin hydration and dermal collagen, and suppressed the collagen-degrading enzyme MMP1; in skin cells its protective effects disappeared when the enzyme AMPK was blocked. The work is in mice and cell cultures only.

#collagen #skin-aging #photoaging #skincare
Research

Chongqing Team Adds Peptide Amphiphiles to Lipid Nanoparticles, Steering mRNA to the Spleen at Over 100 Times Liver Levels

Researchers at the Women and Children's Hospital of Chongqing Medical University built lipid nanoparticles containing two peptide amphiphiles, reporting in ACS Applied Materials & Interfaces. C16TAT, derived from a cell-penetrating peptide, improved mRNA delivery across several cell lines, while C16HA2, based on an endosome-disrupting peptide, changed the particles' charge and produced more than 100-fold higher mRNA expression in the spleen than in the liver in vivo. Particles with TAT attached to their surface worked in cells but performed worse in animals because they were less stable.

#mrna-delivery #lipid-nanoparticles #drug-delivery

Related Guides